1033:
Krarup, AR; Abdel-Mohsen, M; Schleimann, MH; Vibholm, L; Engen, PA; Dige, A; Wittig, B; Schmidt, M; Green, SJ; Naqib, A; Keshavarzian, A; Deng, X; Olesen, R; Petersen, AM; Benfield, T; Ăstergaard, L; Rasmussen, TA; Agnholt, J; Nyengaard, JR; Landay, A; Søgaard, OS; Pillai, SK; Tolstrup, M; Denton, PW
989:
Vibholm, L; Schleimann, MH; Højen, JF; Benfield, T; Offersen, R; Rasmussen, K; Olesen, R; Dige, A; Agnholt, J; Grau, J; Buzon, M; Wittig, B; Lichterfeld, M; Petersen, AM; Deng, X; Abdel-Mohsen, M; Pillai, SK; Rutsaert, S; Trypsteen, W; De
Spiegelaere, W; Vandekerchove, L; Ăstergaard, L; Rasmussen, T;
147:
but received further advice from V.A. Erdmann, O. Pongs, H.-J. Risse, H. Tiedemann and H.G. Wittmann as well. Having concluded his medical studies in 1975, Wittig successfully defended his thesis on "Purification and
Characterisation of the Four Lysine-Specific Transfer Ribonucleic Acids from Chicken
224:
In 1987, Freie
Universitaet Berlin awarded Wittig an extraordinary professorship. He continued to work as a visiting professor at Alexander Rich's lab until 1989, when he became a Schering professor (S-C4, full tenure) at Freie Universitaet Berlin. In 1988, he became the fully tenured founding chair
1172:
Schleimann, MH; Kobberø, ML; Vibholm, LK; KjÌr, K; Giron, LB; Busman-Sahay, K; Chan, CN; Nekorchuk, M; Schmidt, M; Wittig, B; Damsgaard, TE; Ahlburg, P; Hellfritzsch, MB; Zuwala, K; Rothemejer, FH; Olesen, R; Schommers, P; Klein, F; Dweep, H; Kossenkov, A; Nyengaard, JR; Estes, JD; Abdel-Mohsen, M;
661:
Wittig, B; Märten, A; Dorbic, T; Weineck, S; Min, H; Niemitz, S; Trojaneck, B; Flieger, D; Kruopis, S; Albers, A; LÜffel, J; Neubauer, A; Albers, P; Mßller, S; Sauerbruch, T; Bieber, T; Huhn, D; Schmidt-Wolf, IGH (2001). "Therapeutic vaccination against metastatic carcinoma by expression-modulated
327:
Allfrey VG, Arnott S, Bradbury EM, Bayev A, Chambon P, Crick FHC, Felsenfeld G, Mirzabekov AT, Noll M, Stern H, van Holde KE, Wittig B, Zachau HG, and
Zweidler A (1976) âThe Structure of Chromatinâ in: Organization and expression of chromosomes: Dahlem Konferenzen Life Sciences Research Report, 4;
691:
LĂłpez-Fuertes, L; PĂŠrez-JimĂŠnez, E; Vila-Coro, AJ; Sack, F; Moreno, S; Konig, SA; Junghans, C; Wittig, B; TimĂłn, M; Esteban, M (2002). "DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against
Leishmania major infection in mice".
1215:
Schmidt M, Schroff M, Wittig B (2020) âHarnessing the
Therapeutic Potential of Dendritic Cellsâ in: Second Generation Cell and Gene-based Therapies, pp. 183â202; Alain A. Vertès, Devyn M. Smith, Nasib Qureshi, Nathan J. Dowden (Eds.)
1080:"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study"
256:. Two classes of DNA-molecules evolved through theoretical and experimental selection processes and became key technologies; MIDGE (minimalistic, immunogenically defined gene expression), and dSLIM for DNA-based immunomodulation.
723:"Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer"
135:) and graduated by the German Gesellenpruefung. During his time as a medical student at Freie Universitaet Berlin, Wittig joined laboratories at the Institute of Molecular Biology and Biochemistry and at the
620:"Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study"
1077:
Thomas, M; Ponce-Aix, S; Navarro, A; Riera-Knorrenschild, J; Schmidt, M; Wiegert, E; Kapp, K; Wittig, B; Mauri, C; DĂłmine GĂłmez, M; Kollmeier, J; Sadjadian, P; FrĂśhling, K-P; Huber, RM; Wolf, M (2018).
801:
Endmann, A; Baden, M; Weisermann, E; Kapp, K; Schroff, M; Kleuss, C; Wittig, B; Juhls, C (2010). "Immune response induced by a linear DNA vector: Influence of dose, formulation and route of injection".
1488:
479:
Kleuss, C; Hescheler, J; Ewel, C; Rosenthal, W; Schultz, G; Wittig, B (1991). "Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents".
225:
and department head of
Molecular Biology and Bioinformatics at Freie Universitaet's Institute of Molecular Biology and Biochemistry. After a change of the relevant laws of the
1123:"Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors"
259:
Guided by the goal of facilitating the independent transition from basic research into clinical DNA-based medicines, Wittig founded
Mologen AG in 1998. The firm had their
764:
Kneipp, J; Kneipp, H; Wittig, B; Kneipp, K (2007). "One- and two-photon excited optical ph probing for cells using surface-enhanced Raman and hyper-Raman nanosensors".
526:
Kleuss, C; ScherĂźbl, H; Hescheler, J; Schultz, G; Wittig, B (1993). "Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins".
163:
From 1976 to 1986, Wittig attended a variety of physics courses in addition to his principal work as a researcher. These classes led him as a visiting student to
274:
with Freie
Universitaet as the trustee. He served as the chairman of this newly created Foundation Institute of Molecular Biology and Bioinformatics until 2017.
244:
Beginning in 1994, Wittig focused his research on the design, development, and clinical proof-of-concept of covalently closed DNA constructs for the treatment of
721:
Weihrauch, MR; Ansen, S; Jurkiewicz, E; Geisen, C; Xia, Z; Anderson, KS; Gracien, E; Schmidt, M; Wittig, B; Diehl, V; Wolf, J; Bohlen, H; Nadler, LM (2005).
182:
for "Biochemistry and
Molecular Biology" and became thus formally eligible for a full professorship in Germany. For the 1982/83 cycle, Wittig was awarded a
992:"Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection"
136:
1350:
1221:
214:
172:
1483:
267:
in the same year. He served as Mologen AG's CEO until 2007, while continuing to work as a full professor in a private-public-partnership.
911:"Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist"
299:
Wittig, B; Reuter, S; Gottschling, H (1973). "Purification of the four lysine specific transfer ribonucleic acids from chick embryos".
341:
187:
333:
164:
238:
1441:
1228:
O'Halloran, J. A.; et al. (2022). "Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19".
618:
MĂśller, P; Sun, Y; Dorbic, T; Alijagic, S; Makki, A; Jurgovsky, K; Schroff, M; Henz, BM; Wittig, B; Schadendorf, D (1998).
234:
195:
436:""Transcription is associated with Z-DNA formation in metabolically active, permeabilized mammalian cell nuclei"(PDF)"
352:
Wittig, B; Wittig, S (1979). "A phase relationship associates tRNA structural gene sequences with nucleosome cores".
183:
1493:
120:
44:
1454:
190:; he continued to work as a fellow of the programme until 1989. During this time, he spent time at the labs of
153:
1478:
282:
150:
Reinigung und Charakterisierung der vier lysinspezifischen Transfer-Ribonukleinsäuren aus Hßhnerembyronen
271:
264:
1473:
1229:
773:
578:
535:
488:
398:
218:
253:
157:
60:
1270:
241:, Wittig became director of its newly founded Institute of Molecular Biology and Bioinformatics.
1446:
1332:
1160:
977:
752:
512:
422:
377:
230:
206:
56:
389:
Wittig, B; Wittig, S (1982). "Function of a tRNA gene promoter depends on nucleosome position".
1324:
1316:
1234:
1217:
1204:
1152:
1109:
1065:
1021:
969:
940:
897:
862:
819:
789:
744:
709:
679:
649:
606:
551:
504:
467:
414:
369:
337:
329:
316:
88:
40:
876:"MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside"
144:
1308:
1194:
1186:
1142:
1134:
1099:
1091:
1055:
1047:
1036:"The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon"
1011:
1003:
961:
930:
922:
887:
852:
844:
811:
781:
734:
701:
671:
639:
631:
596:
586:
543:
496:
457:
447:
406:
361:
308:
108:
80:
1452:
Burghardt Wittig on the website of MolBioMath - Molecular Biology & Integral Biomathics
1374:
1458:
1431:
249:
226:
191:
48:
1426:
777:
582:
539:
492:
402:
1199:
1174:
1147:
1122:
1104:
1079:
1060:
1035:
1016:
991:
935:
910:
857:
832:
644:
619:
210:
705:
1467:
1164:
892:
875:
601:
566:
462:
435:
365:
312:
75:. His research has been published in numerous leading scientific journals, including
68:
756:
516:
426:
381:
328:
Allfrey AG, Bautz EKF, McCarthy BJ, Schimke RT, Tissieres A (Eds.) pp. 19â27;
76:
36:
1336:
1175:"TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes"
1138:
981:
815:
739:
722:
221:. Wittig would later describe these years as "the most career-shaping of life".
1190:
179:
132:
128:
72:
662:
and immunomodified autologous tumor cells: A first clinical Phase I/II trial".
675:
103:, where he attended the classical "Gymnasium Ernestinum". He graduated by the
1320:
1095:
547:
64:
1328:
1208:
1156:
1113:
1069:
1025:
973:
944:
901:
866:
823:
793:
748:
713:
683:
452:
1296:
653:
610:
591:
555:
508:
471:
418:
320:
1007:
909:
Volz, B; Schmidt, M; Heinrich, K; Kapp, K; Schroff, M; Wittig, B (2015).
848:
635:
373:
124:
926:
286:
1121:
Kapp, K; Volz, B; Oswald, D; Wittig, B; Baumann, M; Schmidt, M (2019).
1051:
270:
In 2010, Wittig's institute returned to Freie Universitaet Berlin as a
168:
28:
1399:
785:
1451:
1312:
965:
500:
410:
245:
140:
104:
199:
127:. While attending medical school, he also received training as an
100:
24:
84:
20:
287:
Gentechnologiestiftung - Dr. Georg und Ingeburg Scheel Stiftung
47:
in Berlin (FUB), Germany. His research focuses on the areas of
260:
52:
1400:"â Researchers â Molecular Biology & Integral Biomathics"
565:
MĂźller, V; Takeya, M; Brendel, S; Wittig, B; Rich, A (1996).
1173:Ăstergaard, L; Tolstrup, M; Søgaard, OS; Denton, PW (2019).
567:"Z-DNA forming sites within the human b-globin gene cluster"
952:
Zhang, S.; Wittig, B. (2015). "Alexander Rich: 1924â2015".
874:
Wittig, B; Schmidt, M; Scheithauer, W; Schmoll, HJ (2015).
1436:
278:
32:
175:). He received no official degree for these courses.
831:Kapp, K; Kleuss, C; Schroff, M; Wittig, B (2014).
1432:patents by Burghardt Wittig on patents.justia.com
1379:Cluster Gesundheitswirtschaft Berlin-Brandenburg
152:) in 1976. He stayed at Freie Universitaet as a
1489:Academic staff of the Free University of Berlin
990:Denton, PW; Tolstrup, M; Søgaard, OS (2017).
171:) and Massachusetts Institute of Technology (
8:
69:therapeutic applications of genetic research
1295:Zhang, Shuguang; Wittig, Burghardt (2015).
137:Max Planck Institute for Molecular Genetics
1233:
1198:
1146:
1103:
1059:
1015:
934:
891:
856:
738:
643:
600:
590:
461:
451:
289:, of which he is currently the chairman
1249:
107:in fall 1966, followed by two years of
434:Wittig, B; Dorbic, T; Rich, A (1991).
205:From 1984 to 1986, Wittig worked as a
167:, California Institute of Technology (
139:to conduct the experiments for his MD
65:G-protein-mediated signal transduction
833:"Genuine Immunomodulation With dSLIM"
7:
1265:
1263:
1261:
1259:
1257:
1255:
1253:
129:engineer specialised in hearing aids
346:Abakon Verlagsgesellschaft, Berlin
198:, Rehovot, and Koki Horikoshi, at
14:
143:. He was principally mentored by
1442:FUB alumni article on Mologen AG
1427:Burghardt Wittig on researchgate
893:10.1016/j.critrevonc.2014.12.002
217:, where he also cooperated with
188:Deutsche Forschungsgemeinschaft
239:CharitĂŠ â Universitaetsmedizin
165:Technische Universitaet Berlin
1:
1351:"dSLIMming the immune system"
1139:10.1080/2162402X.2019.1659096
816:10.1016/j.vaccine.2010.03.034
740:10.1158/1078-0432.ccr-05-0018
706:10.1016/s0264-410x(02)00450-4
285:under the trusteeship of the
277:In late 2019, Wittig founded
196:Weizmann Institute of Science
366:10.1016/0092-8674(79)90230-7
313:10.1016/0005-2787(73)90435-8
1484:German molecular biologists
1235:10.1101/2022.09.22.22280245
1191:10.1016/j.ebiom.2019.07.005
1510:
1297:"Alexander Rich 1924â2015"
571:Proc. Natl. Acad. Sci. USA
440:Proc. Natl. Acad. Sci. USA
676:10.1089/10430340150218404
624:British Journal of Cancer
121:Freie Universitaet Berlin
111:in the German military.
45:Freie Universitaet Berlin
1224:, Academic Press, London
880:Crit Rev Oncol Haematol
548:10.1126/science.8094261
1375:"Biotech & Pharma"
837:Mol Ther Nucleic Acids
453:10.1073/pnas.88.6.2259
301:Biochim. Biophys. Acta
184:Heisenberg scholarship
156:until 1978, and as an
55:structures induced by
1447:Google Scholar report
1096:10.1093/annonc/mdy326
592:10.1073/pnas.93.2.780
293:Selected publications
283:non-profit foundation
272:non-profit foundation
265:German stock exchange
235:Humboldt Universitaet
31:) is the chairman of
1301:Nature Biotechnology
954:Nature Biotechnology
849:10.1038/mtna.2014.28
636:10.1038/bjc.1998.317
219:Alexander Varshavsky
927:10.1038/mto.2015.23
915:Mol Ther Oncolytics
778:2007NanoL...7.2819K
583:1996PNAS...93..780M
540:1993Sci...259..832K
493:1991Natur.353...43K
403:1982Natur.297...31W
254:infectious diseases
160:from 1978 to 1987.
158:assistant professor
119:Wittig enrolled at
115:Career and Research
99:Wittig was born in
61:chromatin structure
35:and a professor of
1457:2020-03-25 at the
1437:Mologen AG website
1271:"Burghardt Wittig"
1084:Annals of Oncology
1052:10.1038/mi.2017.59
1008:10.1093/cid/cix201
664:Human Gene Therapy
534:(832â834): 832â4.
231:Freie Universitaet
207:visiting professor
148:Embryos" (German:
145:Hubert Gottschling
73:DNA-based vaccines
1494:People from Celle
1222:978-0-12-812034-7
1090:(10): 2076â2084.
1002:(12): 1686â1695.
786:10.1021/nl071418z
733:(16): 5993â6001.
630:(11): 1907â1916.
123:in 1968 to study
41:molecular biology
1501:
1414:
1413:
1411:
1410:
1396:
1390:
1389:
1387:
1386:
1371:
1365:
1364:
1362:
1361:
1347:
1341:
1340:
1313:10.1038/nbt.3262
1292:
1286:
1285:
1283:
1282:
1275:www.fu-berlin.de
1267:
1239:
1237:
1212:
1202:
1168:
1150:
1133:(12): e1659096.
1117:
1107:
1073:
1063:
1029:
1019:
985:
966:10.1038/nbt.3262
948:
938:
905:
895:
870:
860:
827:
797:
760:
742:
717:
687:
657:
647:
614:
604:
594:
559:
520:
501:10.1038/353043a0
475:
465:
455:
446:(6): 2259â2263.
430:
411:10.1038/297031a0
385:
360:(4): 1173â1183.
324:
229:merged parts of
178:In 1980, Wittig
57:torsional strain
17:Burghardt Wittig
1509:
1508:
1504:
1503:
1502:
1500:
1499:
1498:
1464:
1463:
1459:Wayback Machine
1423:
1418:
1417:
1408:
1406:
1404:molbio2math.org
1398:
1397:
1393:
1384:
1382:
1373:
1372:
1368:
1359:
1357:
1349:
1348:
1344:
1294:
1293:
1289:
1280:
1278:
1269:
1268:
1251:
1246:
1227:
1171:
1120:
1076:
1040:Mucosal Immunol
1032:
996:Clin Infect Dis
988:
951:
908:
873:
830:
800:
763:
727:Clin Cancer Res
720:
700:(3â4): 247â57.
690:
660:
617:
564:
525:
487:(6339): 43â48.
478:
433:
397:(5861): 31â38.
388:
351:
298:
295:
227:state of Berlin
192:Edward Trifonov
117:
97:
49:gene regulation
12:
11:
5:
1507:
1505:
1497:
1496:
1491:
1486:
1481:
1476:
1466:
1465:
1462:
1461:
1449:
1444:
1439:
1434:
1429:
1422:
1421:External links
1419:
1416:
1415:
1391:
1366:
1342:
1307:(6): 593â598.
1287:
1248:
1247:
1245:
1242:
1241:
1240:
1225:
1213:
1169:
1127:OncoImmunology
1118:
1074:
1046:(2): 449â461.
1030:
986:
960:(6): 593â598.
949:
906:
871:
828:
810:(21): 3642â9.
798:
772:(9): 2819â23.
761:
718:
688:
670:(3): 267â278.
658:
615:
577:(2): 780â784.
561:
560:
522:
521:
476:
431:
386:
349:
325:
307:(2): 221â230.
294:
291:
211:Alexander Rich
116:
113:
101:Celle, Germany
96:
93:
13:
10:
9:
6:
4:
3:
2:
1506:
1495:
1492:
1490:
1487:
1485:
1482:
1480:
1479:Living people
1477:
1475:
1472:
1471:
1469:
1460:
1456:
1453:
1450:
1448:
1445:
1443:
1440:
1438:
1435:
1433:
1430:
1428:
1425:
1424:
1420:
1405:
1401:
1395:
1392:
1380:
1376:
1370:
1367:
1356:
1352:
1346:
1343:
1338:
1334:
1330:
1326:
1322:
1318:
1314:
1310:
1306:
1302:
1298:
1291:
1288:
1276:
1272:
1266:
1264:
1262:
1260:
1258:
1256:
1254:
1250:
1243:
1236:
1231:
1226:
1223:
1219:
1214:
1210:
1206:
1201:
1196:
1192:
1188:
1184:
1180:
1176:
1170:
1166:
1162:
1158:
1154:
1149:
1144:
1140:
1136:
1132:
1128:
1124:
1119:
1115:
1111:
1106:
1101:
1097:
1093:
1089:
1085:
1081:
1075:
1071:
1067:
1062:
1057:
1053:
1049:
1045:
1041:
1037:
1031:
1027:
1023:
1018:
1013:
1009:
1005:
1001:
997:
993:
987:
983:
979:
975:
971:
967:
963:
959:
955:
950:
946:
942:
937:
932:
928:
924:
920:
916:
912:
907:
903:
899:
894:
889:
885:
881:
877:
872:
868:
864:
859:
854:
850:
846:
842:
838:
834:
829:
825:
821:
817:
813:
809:
805:
799:
795:
791:
787:
783:
779:
775:
771:
767:
762:
758:
754:
750:
746:
741:
736:
732:
728:
724:
719:
715:
711:
707:
703:
699:
695:
689:
685:
681:
677:
673:
669:
665:
659:
655:
651:
646:
641:
637:
633:
629:
625:
621:
616:
612:
608:
603:
598:
593:
588:
584:
580:
576:
572:
568:
563:
562:
557:
553:
549:
545:
541:
537:
533:
529:
524:
523:
518:
514:
510:
506:
502:
498:
494:
490:
486:
482:
477:
473:
469:
464:
459:
454:
449:
445:
441:
437:
432:
428:
424:
420:
416:
412:
408:
404:
400:
396:
392:
387:
383:
379:
375:
371:
367:
363:
359:
355:
350:
347:
343:
342:9783820012057
339:
335:
331:
326:
322:
318:
314:
310:
306:
302:
297:
296:
292:
290:
288:
284:
280:
275:
273:
268:
266:
262:
257:
255:
251:
247:
242:
240:
236:
232:
228:
222:
220:
216:
212:
208:
203:
201:
197:
193:
189:
185:
181:
176:
174:
170:
166:
161:
159:
155:
151:
146:
142:
138:
134:
130:
126:
122:
114:
112:
110:
106:
105:German Abitur
102:
94:
92:
90:
86:
82:
78:
74:
70:
67:, as well as
66:
62:
58:
54:
50:
46:
42:
38:
34:
30:
26:
22:
18:
1407:. Retrieved
1403:
1394:
1383:. Retrieved
1378:
1369:
1358:. Retrieved
1354:
1345:
1304:
1300:
1290:
1279:. Retrieved
1277:. 2012-06-04
1274:
1182:
1179:eBioMedicine
1178:
1130:
1126:
1087:
1083:
1043:
1039:
999:
995:
957:
953:
918:
914:
886:(1): 31â44.
883:
879:
840:
836:
807:
803:
769:
765:
730:
726:
697:
693:
667:
663:
627:
623:
574:
570:
531:
527:
484:
480:
443:
439:
394:
390:
357:
353:
345:
304:
300:
276:
269:
258:
250:DNA-vaccines
243:
223:
204:
177:
162:
149:
118:
98:
37:biochemistry
16:
15:
1474:1947 births
1381:(in German)
1185:: 328â340.
843:(6): e170.
180:habilitated
133:audiologist
1468:Categories
1409:2021-06-12
1385:2018-07-09
1360:2018-07-09
1355:BioCentury
1281:2018-07-09
1244:References
334:3820012052
279:MolBioMath
213:'s lab at
95:Early life
33:MolBioMath
1321:1087-0156
1165:203820145
921:: 15023.
766:Nano Lett
237:into the
1455:Archived
1329:26057974
1209:31300344
1157:31741757
1114:30137193
1070:28766555
1034:(2018).
1026:28329286
974:26057974
945:27119114
902:25577571
867:24959843
824:20362204
794:17696561
757:11221907
749:16115944
714:12450700
684:11177563
252:against
248:and for
125:medicine
1230:medRxiv
1200:6642412
1148:6844329
1105:6225892
1061:5796873
1017:5849129
936:4824560
858:4078763
804:Vaccine
774:Bibcode
694:Vaccine
654:9667667
645:2150323
611:8570634
579:Bibcode
556:8094261
536:Bibcode
528:Science
517:4238414
509:1679199
489:Bibcode
472:2006166
427:4247235
419:7070532
399:Bibcode
382:8811309
321:4774407
263:at the
194:at the
186:of the
169:Caltech
154:postdoc
109:service
89:Science
29:Germany
1337:562909
1335:
1327:
1319:
1232:
1220:
1207:
1197:
1163:
1155:
1145:
1112:
1102:
1068:
1058:
1024:
1014:
982:562909
980:
972:
943:
933:
900:
865:
855:
822:
792:
755:
747:
712:
682:
652:
642:
609:
599:
554:
515:
507:
481:Nature
470:
460:
425:
417:
391:Nature
380:
374:519765
372:
340:
332:
319:
246:cancer
141:thesis
87:, and
81:Nature
19:(born
1333:S2CID
1161:S2CID
978:S2CID
753:S2CID
602:40132
513:S2CID
463:51210
423:S2CID
378:S2CID
200:Riken
25:Celle
1325:PMID
1317:ISSN
1218:ISBN
1205:PMID
1153:PMID
1110:PMID
1066:PMID
1022:PMID
970:PMID
941:PMID
898:PMID
863:PMID
820:PMID
790:PMID
745:PMID
710:PMID
680:PMID
650:PMID
607:PMID
552:PMID
505:PMID
468:PMID
415:PMID
370:PMID
354:Cell
338:ISBN
330:ISBN
317:PMID
281:, a
233:and
85:PNAS
77:Cell
71:and
39:and
21:1947
1309:doi
1195:PMC
1187:doi
1143:PMC
1135:doi
1100:PMC
1092:doi
1056:PMC
1048:doi
1012:PMC
1004:doi
962:doi
931:PMC
923:doi
888:doi
853:PMC
845:doi
812:doi
782:doi
735:doi
702:doi
672:doi
640:PMC
632:doi
597:PMC
587:doi
544:doi
532:259
497:doi
485:353
458:PMC
448:doi
407:doi
395:297
362:doi
309:doi
305:331
261:IPO
215:MIT
209:at
202:.
173:MIT
53:DNA
43:at
23:in
1470::
1402:.
1377:.
1353:.
1331:.
1323:.
1315:.
1305:33
1303:.
1299:.
1273:.
1252:^
1203:.
1193:.
1183:45
1181:.
1177:.
1159:.
1151:.
1141:.
1129:.
1125:.
1108:.
1098:.
1088:29
1086:.
1082:.
1064:.
1054:.
1044:11
1042:.
1038:.
1020:.
1010:.
1000:64
998:.
994:.
976:.
968:.
958:33
956:.
939:.
929:.
917:.
913:.
896:.
884:94
882:.
878:.
861:.
851:.
839:.
835:.
818:.
808:28
806:.
788:.
780:.
768:.
751:.
743:.
731:11
729:.
725:.
708:.
698:21
696:.
678:.
668:12
666:.
648:.
638:.
628:77
626:.
622:.
605:.
595:.
585:.
575:93
573:.
569:.
550:.
542:.
530:.
511:.
503:.
495:.
483:.
466:.
456:.
444:88
442:.
438:.
421:.
413:.
405:.
393:.
376:.
368:.
358:18
356:.
344:,
336:/
315:.
303:.
91:.
83:,
79:,
63:,
59:,
51:,
27:,
1412:.
1388:.
1363:.
1339:.
1311::
1284:.
1238:.
1211:.
1189::
1167:.
1137::
1131:8
1116:.
1094::
1072:.
1050::
1028:.
1006::
984:.
964::
947:.
925::
919:3
904:.
890::
869:.
847::
841:3
826:.
814::
796:.
784::
776::
770:7
759:.
737::
716:.
704::
686:.
674::
656:.
634::
613:.
589::
581::
558:.
546::
538::
519:.
499::
491::
474:.
450::
429:.
409::
401::
384:.
364::
348:.
323:.
311::
131:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.